[{"id":"19720944-036d-444d-865d-588a5ff231f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836429","created_at":"2021-04-08T13:52:42.896Z","updated_at":"2024-07-02T16:34:59.219Z","phase":"Phase 1","brief_title":"Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease","source_id_and_acronym":"NCT04836429","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Photofrin (porfimer sodium)"],"overall_status":"Suspended","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 03/17/2025","study_completion_date":" 03/17/2025","last_update_posted":"2024-06-04"},{"id":"ce3343fa-10fb-4d25-ac60-a52a8f5d035a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05374915","created_at":"2022-05-16T12:54:38.932Z","updated_at":"2024-07-02T16:35:04.494Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","source_id_and_acronym":"NCT05374915","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REM-001 therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"f1142c88-f86a-4438-ad44-8930d0b16ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04559685","created_at":"2021-01-18T21:47:35.667Z","updated_at":"2024-07-02T16:35:12.507Z","phase":"Phase 1","brief_title":"Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT04559685","lead_sponsor":"Nader Sanai","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALA sonodynamic therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/15/2021","start_date":" 03/15/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-27"},{"id":"2974135e-ebdf-4d64-8099-6f751a860dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04590664","created_at":"2021-01-18T21:53:39.246Z","updated_at":"2024-07-02T16:35:17.654Z","phase":"Phase 1/2","brief_title":"Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma","source_id_and_acronym":"NCT04590664","lead_sponsor":"Emory University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Visudyne (verteporfin)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2024-02-26"},{"id":"2fbf63a3-c5d3-4871-867d-819c244d5d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02685592","created_at":"2021-01-18T13:05:56.005Z","updated_at":"2024-07-02T16:37:10.399Z","phase":"Phase 4","brief_title":"Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream","source_id_and_acronym":"NCT02685592","lead_sponsor":"Joint Authority for Päijät-Häme Social and Health Care","biomarkers":" TERT • MITF","pipe":" | ","alterations":" TERT mutation","tags":["TERT • MITF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameluz (aminolevulinic acid)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2018-05-30"}]